Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. (SHA: 603707)

Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	1,347	1,210	1,389	658.55	493.55	364.16
Short-Term Investments	-	-	-	-	-	10.46
Trading Asset Securities	897.16	429.66	1.3	259.8	845.79	56.64
Cash & Short-Term Investments	2,244	1,639	1,390	918.35	1,339	431.26
Cash Growth	1.00%	17.96%	51.34%	-31.43%	210.56%	-0.81%
Accounts Receivable	1,042	771.68	974.11	897.75	788.11	407.75
Other Receivables	263.3	230.88	241.94	167.88	107.21	51.6
Receivables	1,305	1,003	1,216	1,066	895.31	459.34
Inventory	3,664	4,158	5,616	4,894	4,457	3,274
Prepaid Expenses	-	11.98	8.46	7.98	10.11	4.6
Other Current Assets	130.31	449.31	64.14	43.62	65.9	119.71
Total Current Assets	7,343	7,262	8,294	6,930	6,768	4,289
Property, Plant & Equipment	1,213	1,235	1,198	827.42	532.83	481.46
Long-Term Investments	72.8	72.48	61.6	26.39	3.26	0.94
Goodwill	128.4	127.61	125.48	114.87	117.56	125.69
Other Intangible Assets	178.47	174.1	118.96	123.85	105.37	77.41
Long-Term Deferred Tax Assets	291.02	348.4	101.47	34.54	21.65	13.27
Long-Term Deferred Charges	282.12	294.24	94.62	77.65	55.52	49.48
Other Long-Term Assets	277.32	10.38	16.31	82.34	116.08	41.4
Total Assets	9,786	9,524	10,010	8,217	7,720	5,078
Accounts Payable	532.2	537.74	505.12	458.87	502.22	487.67
Accrued Expenses	108.18	294.85	88.15	64.56	47.26	49.75
Short-Term Debt	1,661	1,567	1,957	1,571	2,132	1,368
Current Portion of Long-Term Debt	501.89	505.45	0.42	-	-	-
Current Income Taxes Payable	17.43	29.31	0.44	8.73	17.42	28.61
Current Unearned Revenue	21.45	35.93	38.22	25.07	29.08	36.77
Other Current Liabilities	239.35	116.18	115.44	138.56	77.65	62.14
Total Current Liabilities	3,082	3,086	2,705	2,266	2,806	2,033
Long-Term Debt	513.24	512.37	997.36	480.75	1,132	6.17
Long-Term Leases	11.77	13.23	15.94	-	-	-
Long-Term Unearned Revenue	71.91	76.57	84.99	65.51	38.15	34.85
Long-Term Deferred Tax Liabilities	34.36	37.33	39.99	1.42	-	-
Other Long-Term Liabilities	6.17	-	-	-	-	-
Total Liabilities	3,719	3,726	3,843	2,814	3,976	2,074
Common Stock	1,616	1,617	1,617	1,244	934.16	718.47
Additional Paid-In Capital	590.74	601.02	603.59	987.96	157.77	356.37
Retained Earnings	3,783	3,540	3,915	3,123	2,485	1,895
Treasury Stock	-	-27.75	-32.82	-47.3	-14.43	-16.77
Comprensive Income & Other	80.54	72.5	67.9	70.45	159.79	13.82
Total Common Equity	6,070	5,802	6,171	5,378	3,722	2,966
Minority Interest	-3.47	-3.47	-3.47	24.84	22.12	37.6
Shareholders' Equity	6,067	5,798	6,167	5,403	3,745	3,004
Total Liabilities & Equity	9,786	9,524	10,010	8,217	7,720	5,078
Total Debt	2,688	2,598	2,971	2,051	3,264	1,375
Net Cash (Debt)	-444.33	-958.38	-1,581	-1,133	-1,925	-943.27
Net Cash Per Share	-0.28	-0.61	-0.97	-0.72	-1.21	-0.60
Filing Date Shares Outstanding	1,629	1,473	1,653	1,543	1,662	1,554
Total Common Shares Outstanding	1,629	1,473	1,653	1,543	1,662	1,554
Working Capital	4,261	4,175	5,589	4,663	3,962	2,255
Book Value Per Share	3.73	3.94	3.73	3.49	2.24	1.91
Tangible Book Value	5,763	5,500	5,926	5,139	3,500	2,763
Tangible Book Value Per Share	3.54	3.73	3.58	3.33	2.11	1.78
Buildings	-	548.07	448.47	268.49	164.68	154.03
Machinery	-	1,212	981.72	751.74	606.4	389.11
Construction In Progress	-	79.74	250.62	215.26	99.68	64

Source: S&P Capital IQ. Standard template. Financial Sources.